SG Americas Securities LLC acquired a new stake in Jazz Pharmaceuticals (NASDAQ:JAZZ) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 7,799 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,178,000.

A number of other large investors have also recently modified their holdings of JAZZ. Boston Partners bought a new stake in Jazz Pharmaceuticals in the 4th quarter valued at about $161,470,000. Compagnie Lombard Odier SCmA bought a new stake in Jazz Pharmaceuticals in the 4th quarter valued at about $577,000. Bank of New York Mellon Corp lifted its position in Jazz Pharmaceuticals by 18.4% in the 4th quarter. Bank of New York Mellon Corp now owns 1,760,547 shares of the specialty pharmaceutical company’s stock valued at $237,057,000 after purchasing an additional 274,121 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in Jazz Pharmaceuticals by 29.3% in the 4th quarter. Goldman Sachs Group Inc. now owns 755,623 shares of the specialty pharmaceutical company’s stock valued at $101,745,000 after purchasing an additional 171,174 shares during the last quarter. Finally, Two Sigma Investments LP lifted its position in Jazz Pharmaceuticals by 4,096.5% in the 4th quarter. Two Sigma Investments LP now owns 139,877 shares of the specialty pharmaceutical company’s stock valued at $18,834,000 after purchasing an additional 143,377 shares during the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.

JAZZ has been the topic of a number of recent analyst reports. BidaskClub upgraded shares of Jazz Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, May 14th. Wells Fargo & Co set a $182.00 price target on shares of Jazz Pharmaceuticals and gave the stock an “outperform” rating in a research report on Tuesday, May 15th. BMO Capital Markets boosted their price target on shares of Jazz Pharmaceuticals from $199.00 to $201.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 9th. ValuEngine upgraded shares of Jazz Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, May 11th. Finally, B. Riley boosted their price target on shares of Jazz Pharmaceuticals from $206.00 to $211.00 and gave the stock a “buy” rating in a research report on Thursday, May 10th. Six research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. Jazz Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $181.86.

Shares of Jazz Pharmaceuticals opened at $167.09 on Wednesday, according to Marketbeat Ratings. The company has a market capitalization of $9.96 billion, a PE ratio of 17.48, a price-to-earnings-growth ratio of 0.85 and a beta of 0.97. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.88 and a current ratio of 3.00. Jazz Pharmaceuticals has a 12-month low of $128.58 and a 12-month high of $168.64.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings data on Tuesday, February 27th. The specialty pharmaceutical company reported $2.58 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $2.73 by ($0.15). The business had revenue of $436.40 million during the quarter, compared to analyst estimates of $440.91 million. Jazz Pharmaceuticals had a return on equity of 23.78% and a net margin of 26.51%. research analysts forecast that Jazz Pharmaceuticals will post 11.65 EPS for the current fiscal year.

In other news, SVP Karen J. Wilson sold 3,899 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Tuesday, April 10th. The shares were sold at an average price of $155.00, for a total value of $604,345.00. Following the transaction, the senior vice president now owns 19,517 shares of the company’s stock, valued at approximately $3,025,135. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Bruce C. Cozadd sold 1,000 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $150.00, for a total transaction of $150,000.00. Following the completion of the transaction, the chief executive officer now directly owns 267,468 shares in the company, valued at approximately $40,120,200. The disclosure for this sale can be found here. Insiders sold a total of 20,837 shares of company stock worth $3,200,686 in the last ninety days. Corporate insiders own 4.30% of the company’s stock.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals (NASDAQ:JAZZ).

Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.